Preimplantation Genetic Diagnosis (PGD) is recommended for couples in which one or both of the partners are carriers of an inherited genetic disorder. This cutting edge technology involves screening cells from embryos that have been fertilized via Intracytoplasmic Sperm Injection (ICSI). After five to six days of growth, the embryo(s) are biopsied to identify genetic diseases and chromosomal disorders, then cryopreserved. This identification process provides the ability to select only unaffected embryo(s) to use for a frozen embryo transfer (FET). This screening increases the likelihood of having healthy, disease-free babies.
Preimplantation Genetic Screening (PGS) is considered for women who have experienced recurrent pregnancy loss, for defining chromosomal normalcy prior to implantation. PGS applies the technology from PGD to improve chances for a successful pregnancy. Unlike PGD, PGS does not identify the presence of or allow the diagnosis of a genetic disorder. With PGS, embryos are screened for aneuploidy (missing or additional numbers of chromosomes), which is the leading cause of miscarriage and unsuccessful implantation of the embryo into the uterus. The goal of PGS is to identify chromosomally normal embryos which can then be selected for transfer, significantly increasing the chance of pregnancy. It is also used for the purpose of gender selection (usually for family balancing).
RMIA works with various national reference labs (Natera, GoodStart, and RGI) to perform these types of genetic tests.
Patients must meet medical criteria for this treatment.
Click here for costs.